首站-论文投稿智能助手
典型文献
Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019
文献摘要:
Background:Coronavirus disease 2019 (COVID-19) has become a worldwide life-threatening pandemic.Lianhua Qingwen is believed to possess the ability to treat or significantly improve the symptoms of COVID-19.These claims make it important to systematically evaluate the effects of using Lianhua Qingwen with Western medicine to treat COVID-19.Objective:To evaluate the safety and efficacy of combination therapy,employing Lianhua Qingwen with Western medicine,to treat COVID-19,using a meta-analysis approach.Search strategy:China National Knowledge Infrastructure,Wanfang Database,VIP Database,PubMed,Embase,and Cochrane Library databases were searched for studies evaluating the effect of Lianhua Qingwen-Western medicine combination therapy in the treatment of COVID-19.Inclusion criteria:(1) Research object:hospitalized patients meeting the diagnostic criteria of COVID-19 were included.(2) Intervention measures:patients in the treatment group received Lianhua Qingwen treatment combined with Western medicine,while the control group received either Western medicine or Chinese medicine treatment.(3) Research type:randomized controlled trials and retrospective study were included.Data extraction and analysis:Two researchers extracted the first author,the proportion of males and females,age.body temperature,course of treatment,rate of disappearance of main symptoms,duration of fever,adverse reactions,and total effectiveness from the literature.Odds ratio (OR) and 95% confidence interval (CI) were used as the effect value for count data,and mean difference (MD) and 95% CI were used as the effect value for measurement data.Results:Six articles met the inclusion criteria,including a total of 856 COVID-19 patients.The meta-analysis showed that Lianhua Qingwen combination therapy achieved higher rates of fever reduc-tion (OR =3.43,95% CI[1.78,6.59],P =0.0002),cough reduction (OR =3.39,95% CI[1.85,6.23],P < 0.0001),recovery from shortness of breath (OR =10.62,95% CI[3.71,30.40],P < 0.0001) and recovery from fatigue (OR =2.82,95% CI[1.44,5.53],P =0.003),higher total effectiveness rate (OR =2.51,95% CI[1.73,3.64],P < 0.00001),and shorter time to recovery from fever (MD =-1.00,95% CI[1.04,0.96],P < 0.00001),and did not increase the adverse reaction rate (OR =0.65,95% CI[0.42,1.01],P =0.06),com-pared to the single medication control.Conclusion:The Lianhua Qingwen and Western medicine combination therapy is highly effective for COVID-19 patients and has good clinical safety.As only a small number of studies and patients were included in this review,more high-quality,multicenter,large-sample-size,randomized,double-blind,controlled trials are still needed for verification.
文献关键词:
作者姓名:
Deng-chao Wang;Miao Yu;Wen-xian Xie;Li-yan Huang;Jian Wei;Yue-hua Lei
作者机构:
Department of General Surgery,Zigong Fourth People's Hospital,Zigong 643000,Sichuan Province,China;Department of Basic Medicine,Sichuan Vocational College of Health and Rehabilitation,Zigong 643000,Sichuan Province,China;Department of Pathology,West China Second Hospital of Sichuan University,Chengdu 610000,Sichuan Province,China
引用格式:
[1]Deng-chao Wang;Miao Yu;Wen-xian Xie;Li-yan Huang;Jian Wei;Yue-hua Lei-.Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019)[J].结合医学学报(英文版),2022(01):26-33
A类:
B类:
analysis,combining,Lianhua,Qingwen,medicine,coronavirus,disease,Background,Coronavirus,has,become,worldwide,life,threatening,pandemic,believed,possess,ability,significantly,improve,symptoms,These,claims,make,important,systematically,evaluate,effects,using,Objective,To,safety,efficacy,combination,therapy,employing,meta,approach,Search,strategy,China,National,Knowledge,Infrastructure,Wanfang,Database,VIP,Embase,Cochrane,Library,databases,were,searched,studies,evaluating,treatment,Inclusion,criteria,Research,object,hospitalized,patients,meeting,diagnostic,included,Intervention,measures,group,received,combined,while,either,Chinese,type,randomized,controlled,trials,retrospective,study,extraction,Two,researchers,extracted,first,author,proportion,females,age,body,temperature,course,disappearance,main,duration,fever,adverse,reactions,total,effectiveness,from,literature,Odds,confidence,interval,used,value,count,mean,difference,MD,measurement,Results,Six,articles,inclusion,including,showed,that,achieved,higher,rates,cough,reduction,recovery,shortness,breath,fatigue,shorter,did,not,increase,pared,single,medication,Conclusion,highly,good,clinical,only,small,number,this,review,more,quality,multicenter,large,sample,size,double,blind,still,needed,verification
AB值:
0.488448
相似文献
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Moxibustion for COVID-19: a systematic scoping review
Meng Xia;Bo Pang;Shaowei Yi;Xinjue Shan;Shizhe Deng;Yinan Qin;Tao Jiang;Hai Lu-Alberta College of Acupuncture&Traditional Chinese Medicine,Alberta,Canada;Evidence-based Medicine Center,TianjinUniversity of Traditional Chinese Medicine,Tianjin,China;School of Acupuncture-moxibustion and Tuina,Tianjin University of Traditional Chinese Medicine,Tianjin,China;School of Traditional ChineseMedicine,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Department of Acupuncture and Moxibustion,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin,China;School of Acupuncture-moxibustion and Tuina,Shaanxi University of Chinese Medicine,Xianyang,China;Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。